Director’s Advisory Committee meeting in February that there be a rapid 
dissemination of research and safety results in recombinant DNA research. 
I would especially welcome your thoughts on this matter. What experience, 
if any, have you or your colleagues or institution had with patent 
claims in this regard? I would especially appreciate your views on 
Department patent policy as it relates to the suggested policy options I 
have outlined above. I intend also to solicit advice on this matter 
from other interested parties in the scientific community and public and 
private sectors. 
Thank you very much for your consideration of this most important matter. 
In order that we might be able to respond to Stanford in a timely fashion, 
I would appreciate your comments by October 1. 
Sincerely yours, 
/s/ 
Donald S. Fredrickson, M.D. 
Director 
1-4 
[ 24 ] 
